On the public citation graph

Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy

https://doi.org/10.1200/jco.2011.40.3774

0 signed · 367 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cncr.11335openalex-snapshot

Tissue microarray‐based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors

inferredcites →https://doi.org/10.1002/ijc.20598openalex-snapshot

C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu

inferredcites →https://doi.org/10.1002/ijc.26137openalex-snapshot

A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors

inferredcites →https://doi.org/10.1002/j.1460-2075.1992.tb05315.xopenalex-snapshot

Structure‐function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding.

inferredcites →https://doi.org/10.1002/jcb.10358openalex-snapshot

HGF/SF‐met signaling in the control of branching morphogenesis and invasion

inferredcites →https://doi.org/10.1007/s12094-010-0501-0openalex-snapshot

C-MET as a new therapeutic target for the development of novel anticancer drugs

inferredcites →https://doi.org/10.1016/0270-9139(91)90068-7openalex-snapshot

Hepatocyte growth factor receptor and the c-met oncogene Bottaro DP, Rubin JS, Faletto DL, Chan AM-L, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802?804

inferredcites →https://doi.org/10.1016/j.bbrc.2005.06.198openalex-snapshot

Role of PYK2 in the development of obesity and insulin resistance

inferredcites →https://doi.org/10.1016/j.canlet.2004.09.044openalex-snapshot

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention

inferredcites →https://doi.org/10.1016/j.canlet.2008.02.049openalex-snapshot

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases

inferredcites →https://doi.org/10.1016/j.ccr.2004.05.032openalex-snapshot

Targeting the tumor and its microenvironment by a dual-function decoy Met receptor

inferredcites →https://doi.org/10.1016/j.ccr.2004.06.013openalex-snapshot

The Sema domain of Met is necessary for receptor dimerization and activation

inferredcites →https://doi.org/10.1016/j.ccr.2011.11.024openalex-snapshot

Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway

inferredcites →https://doi.org/10.1016/j.ejca.2010.02.028openalex-snapshot

Targeting the HGF/Met signalling pathway in cancer

inferredcites →https://doi.org/10.1016/j.humpath.2006.11.015openalex-snapshot

Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype

inferredcites →https://doi.org/10.1016/j.lungcan.2008.06.011openalex-snapshot

MET as a target for treatment of chest tumors

inferredcites →https://doi.org/10.1016/j.molmed.2005.04.005openalex-snapshot

Cancer therapy: can the challenge be MET?

inferredcites →https://doi.org/10.1016/s0021-9258(18)99953-9openalex-snapshot

Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF.

inferredcites →https://doi.org/10.1016/s0092-8674(01)00567-0openalex-snapshot

A Signaling Adapter Function for α6β4 Integrin in the Control of HGF-Dependent Invasive Growth

inferredcites →https://doi.org/10.1016/s0962-8924(03)00104-1openalex-snapshot

How to make tubes: signaling by the Met receptor tyrosine kinase

inferredcites →https://doi.org/10.1016/s1359-6349(08)72345-0openalex-snapshot

411 POSTER A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors

inferredcites →https://doi.org/10.1038/bjc.1996.646openalex-snapshot

Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas

inferredcites →https://doi.org/10.1038/ng0597-68openalex-snapshot

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

inferredcites →https://doi.org/10.1038/nrc1912openalex-snapshot

Invasive growth: a MET-driven genetic programme for cancer and stem cells

inferredcites →https://doi.org/10.1038/sj.emboj.7600243openalex-snapshot

Crystal structure of the HGF β‐chain in complex with the Sema domain of the Met receptor

inferredcites →https://doi.org/10.1038/sj.onc.1202899openalex-snapshot

Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists

inferredcites →https://doi.org/10.1038/sj.onc.1203455openalex-snapshot

Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas

inferredcites →https://doi.org/10.1038/sj.onc.1203874openalex-snapshot

A novel germ line juxtamembrane Met mutation in human gastric cancer

inferredcites →https://doi.org/10.1038/sj.onc.1204253openalex-snapshot

Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis?

inferredcites →https://doi.org/10.1038/sj.onc.1210201openalex-snapshot

From Tpr-Met to Met, tumorigenesis and tubes

inferredcites →https://doi.org/10.1038/sj.onc.1210271openalex-snapshot

Ras effector pathways modulate scatter factor-stimulated NF-κB signaling and protection against DNA damage

inferredcites →https://doi.org/10.1046/j.1432-1327.1999.00507.xopenalex-snapshot

Deregulation of the signaling pathways controlling urokinase production

inferredcites →https://doi.org/10.1073/pnas.0407651101openalex-snapshot

Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele

inferredcites →https://doi.org/10.1073/pnas.0508156103openalex-snapshot

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

inferredcites →https://doi.org/10.1073/pnas.0508776103openalex-snapshot

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

inferredcites →https://doi.org/10.1073/pnas.0509040103openalex-snapshot

Structural basis of hepatocyte growth factor/scatter factor and MET signalling

inferredcites →https://doi.org/10.1073/pnas.0710052104openalex-snapshot

Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma

inferredcites →https://doi.org/10.1073/pnas.2034936100openalex-snapshot

Functional map and domain structure of MET, the product of the c- met protooncogene and receptor for hepatocyte growth factor/scatter factor

inferredcites →https://doi.org/10.1073/pnas.88.11.4892openalex-snapshot

The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions.

inferredcites →https://doi.org/10.1074/jbc.m707733200openalex-snapshot

Hepatocyte-specific c-Met Deletion Disrupts Redox Homeostasis and Sensitizes to Fas-mediated Apoptosis

inferredcites →https://doi.org/10.1093/neuonc/noq198openalex-snapshot

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

inferredcites →https://doi.org/10.1111/j.1349-7006.1996.tb03111.xopenalex-snapshot

Expression of c‐met/HGF Receptor in Human Non‐small Cell Lung Carcinomas in vitro and in vivo and Its Prognostic Significance

inferredcites →https://doi.org/10.1111/j.1349-7006.2003.tb01440.xopenalex-snapshot

NK4 (HGF‐antagonist/angiogenesis inhibitor) in cancer biology and therapeutics

inferredcites →https://doi.org/10.1111/j.1464-410x.2010.09947.xopenalex-snapshot

A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma

inferredcites →https://doi.org/10.1124/dmd.107.019711openalex-snapshot

Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models

inferredcites →https://doi.org/10.1126/science.1141478openalex-snapshot

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

inferredcites →https://doi.org/10.1126/science.1720571openalex-snapshot

Identification of a Competitive HGF Antagonist Encoded by an Alternative Transcript

inferredcites →https://doi.org/10.1126/science.1846706openalex-snapshot

Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product

inferredcites →https://doi.org/10.1128/mcb.25.16.6889-6898.2005openalex-snapshot

Semaphorin 4D/Plexin-B1 Induces Endothelial Cell Migration through the Activation of PYK2, Src, and the Phosphatidylinositol 3-Kinase–Akt Pathway

inferredcites →https://doi.org/10.1158/0008-5472.can-04-2650openalex-snapshot

Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer

inferredcites →https://doi.org/10.1158/0008-5472.can-04-4567openalex-snapshot

Functional Analysis of c-Met/Hepatocyte Growth Factor Pathway in Malignant Pleural Mesothelioma

inferredcites →https://doi.org/10.1158/0008-5472.can-05-2749openalex-snapshot

Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer

inferredcites →https://doi.org/10.1158/0008-5472.can-06-4443openalex-snapshot

An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

inferredcites →https://doi.org/10.1158/0008-5472.can-07-5962openalex-snapshot

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

inferredcites →https://doi.org/10.1158/0008-5472.can-08-2881openalex-snapshot

The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma

inferredcites →https://doi.org/10.1158/0008-5472.can-10-0436openalex-snapshot

MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors

inferredcites →https://doi.org/10.1158/0008-5472.can-10-1623openalex-snapshot

Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

inferredcites →https://doi.org/10.1158/1078-0432.ccr-05-1793openalex-snapshot

Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.

inferredcites →https://doi.org/10.1158/1078-0432.ccr-06-0776openalex-snapshot

c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma

inferredcites →https://doi.org/10.1158/1078-0432.ccr-08-1306openalex-snapshot

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

inferredcites →https://doi.org/10.1158/1078-0432.ccr-09-1365openalex-snapshot

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors

inferredcites →https://doi.org/10.1158/1078-0432.ccr-10-0574openalex-snapshot

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

inferredcites →https://doi.org/10.1158/1535-7163.mct-05-0175openalex-snapshot

Regulatory role of c-Met in insulin-like growth factor-I receptor–mediated migration and invasion of human pancreatic carcinoma cells

inferredcites →https://doi.org/10.1158/1535-7163.mct-09-0824openalex-snapshot

Biochemical Characterization of AMG 102: A Neutralizing, Fully Human Monoclonal Antibody to Human and Nonhuman Primate Hepatocyte Growth Factor

inferredcites →https://doi.org/10.1158/1535-7163.targ-09-a100openalex-snapshot

Abstract A100: A phase 1, first in human, study of SCH 900105, an antihepatocyte growth factor (HGF) monoclonal antibody, in subjects with advanced solid tumors

inferredcites →https://doi.org/10.1159/000011985openalex-snapshot

Clinical Significance of c-met Oncogene Alterations in Human Colorectal Cancer

inferredcites →https://doi.org/10.1159/000227594openalex-snapshot

Hepatocyte Growth Factor and c-Met/Hepatocyte Growth Factor Receptor in Pulmonary Adenocarcinomas: An Evaluation of Their Expression as Prognostic Markers

inferredcites →https://doi.org/10.1172/jci0215418openalex-snapshot

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

inferredcites →https://doi.org/10.1172/jci15418openalex-snapshot

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

inferredcites →https://doi.org/10.1172/jci200422235openalex-snapshot

An uncleavable form of pro–scatter factor suppresses tumor growth and dissemination in mice

inferredcites →https://doi.org/10.1186/bcr2239openalex-snapshot

FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors

inferredcites →https://doi.org/10.1200/jco.2008.19.1635openalex-snapshot

Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients

inferredcites →https://doi.org/10.1200/jco.2008.26.15_suppl.4572openalex-snapshot

Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study

inferredcites →https://doi.org/10.1200/jco.2008.26.15_suppl.5103openalex-snapshot

A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)

inferredcites →https://doi.org/10.1200/jco.2009.27.15_suppl.8001openalex-snapshot

SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC

inferredcites →https://doi.org/10.1200/jco.2009.27.15_suppl.e14525openalex-snapshot

Phase I study of daily administration of MGCD265 to patients with advanced malignancies (Study 265–101)

inferredcites →https://doi.org/10.1200/jco.2010.28.15_suppl.3017openalex-snapshot

A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).

inferredcites →https://doi.org/10.1200/jco.2010.28.15_suppl.3081openalex-snapshot

Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.

inferredcites →https://doi.org/10.1200/jco.2010.28.15_suppl.4137openalex-snapshot

Final results from ARQ 197-114: A phase Ib safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC).

inferredcites →https://doi.org/10.1200/jco.2010.28.15_suppl.e13050openalex-snapshot

Phase Ib dose-escalation study of MetMAb, a monovalent antagonist antibody to the receptor MET, in combination with bevacizumab in patients with locally advanced or metastatic solid tumors.

inferredcites →https://doi.org/10.1200/jco.2010.28.15_suppl.e13056openalex-snapshot

A phase I, open-label, nonrandomized trial of OPB-31121, a STAT3 inhibitor, in patients with advanced solid tumors.

inferredcites →https://doi.org/10.1200/jco.2010.31.0367openalex-snapshot

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

inferredcites →https://doi.org/10.1200/jco.2010.32.4145openalex-snapshot

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

inferredcites →https://doi.org/10.1200/jco.2010.34.0570openalex-snapshot

Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1200/jco.2010.34.2139openalex-snapshot

Effective Use of Thalidomide in the Treatment of Recurrent Metastatic Chordoma

inferredcites →https://doi.org/10.1200/jco.2010.34.4481openalex-snapshot

Allogeneic Hematopoietic Stem-Cell Transplantation for Myeloma: It's Time for the Appropriate Studies

inferredcites →https://doi.org/10.1200/jco.2011.29.15_suppl.3083openalex-snapshot

MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with erlotinib: Phase I clinical experience.

inferredcites →https://doi.org/10.1200/jco.2011.29.15_suppl.3500openalex-snapshot

A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses.

inferredcites →https://doi.org/10.1200/jco.2011.29.15_suppl.4516openalex-snapshot

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

inferredcites →https://doi.org/10.1200/jco.2011.29.15_suppl.7505openalex-snapshot

Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.

inferredcites →https://doi.org/10.1200/jco.2011.29.15_suppl.7529openalex-snapshot

Exploratory biomarker analyses from OAM4558g: A placebo-controlled phase II study of erlotinib with or without MetMAb in patients with advanced non-small cell lung cancer (NSCLC).

inferredcites →https://doi.org/10.1200/jco.2011.29.15_suppl.7571openalex-snapshot

Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.

inferredcites →https://doi.org/10.1200/jco.2011.29.15_suppl.tps213openalex-snapshot

Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.

inferredcites →https://doi.org/10.1200/jco.2011.29.4_suppl.493openalex-snapshot

Microsatellite instability status as a predictive marker of clinical outcome from FOLFOX adjuvant chemotherapy in stage III colon cancer.

inferredcites →https://doi.org/10.1200/jco.2012.30.15_suppl.4504openalex-snapshot

Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).

inferredcites →https://doi.org/10.1200/jco.2012.30.5_suppl.115openalex-snapshot

A multicenter, randomized phase II study of rilotumumab (R) (AMG 102) or placebo (Pbo) plus mitoxantrone (M) and prednisone (P) in patients (pts) with previously treated castrate-resistant prostate cancer (CRPC).

inferredcites →https://doi.org/10.1200/jco.2012.30.5_suppl.364openalex-snapshot

Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).

inferredcites →https://doi.org/10.2741/2813openalex-snapshot

NK4 gene therapy targeting HGF-Met and angiogenesis

inferredcites →https://doi.org/10.3171/ped.2004.100.2.0187openalex-snapshot

Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization

inferredcites →https://doi.org/10.4103/1477-3163.44372openalex-snapshot

Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4662549openalex-extracted

Design, Synthesis and Pharmacological Evaluation of Novel Thiazole-Based Peptide Like Molecules as C-Met Kinase Inhibitors and Anticancer Agents

inferred← citeshttps://doi.org/10.2139/ssrn.4825221openalex-extracted

The Hepatocyte Growth Factor/Cmet Axis in Autoimmune Cardiac Inflammation and Beyond

inferred← citeshttps://doi.org/10.1001/jamaoncol.2016.5580openalex-snapshot

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma

inferred← citeshttps://doi.org/10.1001/jamaoto.2015.2381openalex-snapshot

Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti–Hepatocyte Growth Factor Antibody Ficlatuzumab

inferred← citeshttps://doi.org/10.1002/1878-0261.12039openalex-snapshot

Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells

inferred← citeshttps://doi.org/10.1002/1878-0261.12949openalex-snapshot

Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer

inferred← citeshttps://doi.org/10.1002/9781119300229.ch2openalex-snapshot

The Role of HGF / MET and MSP / RON Signaling in Tumor Progression and Resistance to Anticancer Therapy

inferred← citeshttps://doi.org/10.1002/cncr.29029openalex-snapshot

Toward operative in vivo fluorescence imaging of the c‐ M et proto‐oncogene for personalization of therapy in ovarian cancer

inferred← citeshttps://doi.org/10.1002/cnr2.1802openalex-snapshot

Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review

inferred← citeshttps://doi.org/10.1002/ijc.31550openalex-snapshot

Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody‐“decoy” strategy

inferred← citeshttps://doi.org/10.1002/ijc.31624openalex-snapshot

Profiles of brain metastases: Prioritization of therapeutic targets

inferred← citeshttps://doi.org/10.1002/jhet.4589openalex-snapshot

Pyridazinones: A versatile scaffold in the development of potential target‐based novel anticancer agents

inferred← citeshttps://doi.org/10.1002/path.5287openalex-snapshot

c‐Met‐dependent phosphorylation of RhoA plays a key role in gastric cancer tumorigenesis

inferred← citeshttps://doi.org/10.1002/ueg2.12375openalex-snapshot

Colorectal polyps: Targets for fluorescence‐guided endoscopy to detect high‐grade dysplasia and T1 colorectal cancer

inferred← citeshttps://doi.org/10.1002/viw.20230029openalex-snapshot

Molecular imaging of pancreatic ductal adenocarcinoma

inferred← citeshttps://doi.org/10.1007/978-1-4419-9464-6_47openalex-snapshot

Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

inferred← citeshttps://doi.org/10.1007/978-1-4614-8815-6_5openalex-snapshot

The Role of HGF/c-MET in Head and Neck Squamous Cell Carcinoma

inferred← citeshttps://doi.org/10.1007/978-3-030-72702-4_8openalex-snapshot

Therapeutic Intervention of Signaling Pathways in Colorectal Cancer

inferred← citeshttps://doi.org/10.1007/978-3-319-14340-8_1openalex-snapshot

Growth Factors and Tyrosine Kinase Receptors

inferred← citeshttps://doi.org/10.1007/978-3-319-19986-3_13openalex-snapshot

Targeted Therapies For Intestinal Tumorigenesis

inferred← citeshttps://doi.org/10.1007/978-3-319-27601-4_42openalex-snapshot

Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

inferred← citeshttps://doi.org/10.1007/978-3-319-27647-2_5openalex-snapshot

Molecular Signaling in Oral Cancer Invasion and Metastasis

inferred← citeshttps://doi.org/10.1007/978-3-319-28140-7_23openalex-snapshot

Hepatocyte Growth Factor

inferred← citeshttps://doi.org/10.1007/978-3-319-78762-6_3openalex-snapshot

c-MET in Head and Neck Squamous Cell Carcinoma

inferred← citeshttps://doi.org/10.1007/978-981-19-6442-8_12openalex-snapshot

Gallbladder Cancer: Epigenetic Landscape, Targeted Therapy, and Prospect of Epitherapy

inferred← citeshttps://doi.org/10.1007/s00106-012-2596-9openalex-snapshot

Neue Therapieaspekte bei Rezidiv und Fernmetastase des Kopf- und Hals-Karzinoms

inferred← citeshttps://doi.org/10.1007/s00259-017-3672-xopenalex-snapshot

89Zr-Onartuzumab PET imaging of c-MET receptor dynamics

inferred← citeshttps://doi.org/10.1007/s00404-013-3126-zopenalex-snapshot

Effects of MACC1 siRNA on biological behaviors of HeLa

inferred← citeshttps://doi.org/10.1007/s00784-017-2099-xopenalex-snapshot

Biological predictors of radiosensitivity in head and neck squamous cell carcinoma

inferred← citeshttps://doi.org/10.1007/s10266-021-00625-0openalex-snapshot

Targeting hepatocyte growth factor in epithelial–stromal interactions in an in vitro experimental model of human periodontitis

inferred← citeshttps://doi.org/10.1007/s10549-013-2741-5openalex-snapshot

Role of HGF in obesity-associated tumorigenesis: C3(1)-TAg mice as a model for human basal-like breast cancer

inferred← citeshttps://doi.org/10.1007/s10549-016-3812-1openalex-snapshot

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

inferred← citeshttps://doi.org/10.1007/s10637-017-0513-5openalex-snapshot

Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer

inferred← citeshttps://doi.org/10.1007/s10637-018-0588-7openalex-snapshot

A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers

inferred← citeshttps://doi.org/10.1007/s11030-020-10067-5openalex-snapshot

Synthesis of triazolotriazine derivatives as c-Met inhibitors

inferred← citeshttps://doi.org/10.1007/s11523-015-0412-7openalex-snapshot

Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: ‘Game Over’?

inferred← citeshttps://doi.org/10.1007/s11523-016-0425-xopenalex-snapshot

Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial

inferred← citeshttps://doi.org/10.1007/s12032-017-0918-1openalex-snapshot

Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma

inferred← citeshttps://doi.org/10.1007/s12094-014-1258-7openalex-snapshot

The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer

inferred← citeshttps://doi.org/10.1007/s12094-015-1409-5openalex-snapshot

Is c-Met oncoprotein expression an adverse prognosticator in extrahepatic bile duct cancer treated with curative resection followed by adjuvant chemoradiotherapy?

inferred← citeshttps://doi.org/10.1007/s13237-025-00548-zopenalex-snapshot

Role of miR-23b in the carcinogenesis and therapeutics of cervical cancer

inferred← citeshttps://doi.org/10.1007/s13346-024-01564-3openalex-snapshot

Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies

inferred← citeshttps://doi.org/10.1007/s40336-014-0050-6openalex-snapshot

Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

inferred← citeshttps://doi.org/10.1016/b978-0-12-821584-5.00019-5openalex-snapshot

Use of MET kinase inhibitors to overcome cetuximab resistance in colorectal cancer

inferred← citeshttps://doi.org/10.1016/b978-0-323-24098-7.00005-8openalex-snapshot

Biologics and Their Interactions with Radiation

inferred← citeshttps://doi.org/10.1016/b978-0-323-52357-8.00048-2openalex-snapshot

New Targets for Therapy in Lung Cancer

inferred← citeshttps://doi.org/10.1016/b978-0-323-52357-8.00049-4openalex-snapshot

Management of Toxicities of Targeted Therapies

inferred← citeshttps://doi.org/10.1016/b978-0-323-67241-2.00013-6openalex-snapshot

Gastrointestinal Toxicities of Targeted Therapy

inferred← citeshttps://doi.org/10.1016/b978-0-443-44181-3.00005-9openalex-snapshot

Targeted therapy advancements in tumor biology

inferred← citeshttps://doi.org/10.1016/b978-1-4377-1637-5.00005-5openalex-snapshot

Biologics and Their Interactions with Radiation

inferred← citeshttps://doi.org/10.1016/j.anl.2026.04.003openalex-snapshot

Molecular biologic and Epstein-Barr virologic advances in extranodal natural killer/T cell lymphoma over the past four decades

inferred← citeshttps://doi.org/10.1016/j.canlet.2021.04.029openalex-snapshot

Inhibition of c-MET reverses radiation-induced malignant potential in pancreatic cancer

inferred← citeshttps://doi.org/10.1016/j.clbc.2014.06.001openalex-snapshot

Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit

inferred← citeshttps://doi.org/10.1016/j.clgc.2014.06.017openalex-snapshot

MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors

inferred← citeshttps://doi.org/10.1016/j.critrevonc.2013.11.006openalex-snapshot

Targeting the MET gene for the treatment of non-small-cell lung cancer

inferred← citeshttps://doi.org/10.1016/j.critrevonc.2015.08.004openalex-snapshot

Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies

inferred← citeshttps://doi.org/10.1016/j.critrevonc.2020.103192openalex-snapshot

Gynecologic cancers and non-coding RNAs: Epigenetic regulators with emerging roles

inferred← citeshttps://doi.org/10.1016/j.cytogfr.2021.10.006openalex-snapshot

Pro-angiogenic activity and vasculogenic mimicry in the tumor microenvironment by leptin in cancer

inferred← citeshttps://doi.org/10.1016/j.devcel.2014.03.024openalex-snapshot

Tensin-4-Dependent MET Stabilization Is Essential for Survival and Proliferation in Carcinoma Cells

inferred← citeshttps://doi.org/10.1016/j.drup.2018.01.002openalex-snapshot

Redundant angiogenic signaling and tumor drug resistance

inferred← citeshttps://doi.org/10.1016/j.ejca.2013.12.004openalex-snapshot

Molecular alterations and emerging targets in castration resistant prostate cancer

inferred← citeshttps://doi.org/10.1016/j.ejca.2014.05.007openalex-snapshot

Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients

inferred← citeshttps://doi.org/10.1016/j.ejca.2016.06.006openalex-snapshot

Human papillomavirus oncoprotein E6 upregulates c-Met through p53 downregulation

inferred← citeshttps://doi.org/10.1016/j.ejmech.2014.04.056openalex-snapshot

Discovery of novel type II c-Met inhibitors based on BMS-777607

inferred← citeshttps://doi.org/10.1016/j.ejmech.2015.03.041openalex-snapshot

Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis

inferred← citeshttps://doi.org/10.1016/j.ejmech.2017.08.044openalex-snapshot

Recent advances in the discovery of small molecule c-Met Kinase inhibitors

inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116470openalex-snapshot

Pyrrole-containing hybrids as potential anticancer agents: An insight into current developments and structure-activity relationships

inferred← citeshttps://doi.org/10.1016/j.ejphar.2016.09.007openalex-snapshot

Theanine from tea and its semi-synthetic derivative TBrC suppress human cervical cancer growth and migration by inhibiting EGFR/Met-Akt/NF-κB signaling

inferred← citeshttps://doi.org/10.1016/j.humpath.2018.04.027openalex-snapshot

The implications of TrkA and MET aberrations in de novo salivary duct carcinoma

inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2021.05.164openalex-snapshot

Salmon sperm DNA binding study to cabozantinib, a tyrosine kinase inhibitor: Multi-spectroscopic and molecular docking approaches

inferred← citeshttps://doi.org/10.1016/j.ijrobp.2013.11.013openalex-snapshot

c-Met Expression Is a Marker of Poor Prognosis in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Treated With Chemoradiation

inferred← citeshttps://doi.org/10.1016/j.jtbi.2017.11.025openalex-snapshot

Activation of the HGF/c-Met axis in the tumor microenvironment: A multispecies model

inferred← citeshttps://doi.org/10.1016/j.lungcan.2019.04.028openalex-snapshot

c-MET as a biomarker in patients with surgically resected non-small cell lung cancer

inferred← citeshttps://doi.org/10.1016/j.molonc.2013.12.014openalex-snapshot

Prevention of BMS‐777607‐induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics

inferred← citeshttps://doi.org/10.1016/j.molonc.2015.05.007openalex-snapshot

Inhibition of ligand‐independent constitutive activation of the Met oncogenic receptor by the engineered chemically‐modified antibody DN30

inferred← citeshttps://doi.org/10.1016/j.molonc.2016.03.004openalex-snapshot

Dual Constant Domain‐Fab: A novel strategy to improve half‐life and potency of a Met therapeutic antibody

inferred← citeshttps://doi.org/10.1016/j.molstruc.2023.137281openalex-snapshot

Comparison on biological inspection, optimization, cyclic voltammetry, and molecular docking evaluation of novel bivalent transition metal chelates of Schiff Base pincer ligand

inferred← citeshttps://doi.org/10.1016/j.molstruc.2024.139074openalex-snapshot

Design, synthesis and pharmacological evaluation of novel thiazole derivatives as c-Met kinase inhibitors and anticancer agents

inferred← citeshttps://doi.org/10.1016/j.neo.2021.09.006openalex-snapshot

Ovulation sources coagulation protease cascade and hepatocyte growth factor to support physiological growth and malignant transformation

inferred← citeshttps://doi.org/10.1016/j.oraloncology.2014.11.012openalex-snapshot

Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck

inferred← citeshttps://doi.org/10.1016/j.pharmthera.2014.04.005openalex-snapshot

Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer

inferred← citeshttps://doi.org/10.1016/j.semcancer.2016.08.008openalex-snapshot

Smyd3-associated regulatory pathways in cancer

inferred← citeshttps://doi.org/10.1016/j.snb.2026.139673openalex-snapshot

Deep learning enabled magnetic/rare earth hybrid nanorobots for multi-modal bioimaging and temperature sensing with surgical boundary determination

inferred← citeshttps://doi.org/10.1016/j.tjog.2018.11.020openalex-snapshot

Clinical significance of c-Met and phospho-c-Met (Tyr1234/1235) in ovarian cancer

inferred← citeshttps://doi.org/10.1016/j.yexcr.2014.04.009openalex-snapshot

Inhibition of transforming growth factor-β signaling potentiates tumor cell invasion into collagen matrix induced by fibroblast-derived hepatocyte growth factor

inferred← citeshttps://doi.org/10.1016/s0140-6736(13)61719-5openalex-snapshot

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

inferred← citeshttps://doi.org/10.1016/s0140-6736(15)01088-0openalex-snapshot

Antiangiogenic therapy in oncology: current status and future directions

inferred← citeshttps://doi.org/10.1016/s1877-1203(16)30031-3openalex-snapshot

Carcinomes bronchiques non à petites cellules (CBNPC) métastatiques, mutés ou réarrangés : comment déterminer la cible ?

inferred← citeshttps://doi.org/10.1016/s1877-1203(16)30033-7openalex-snapshot

Ciblage de MET, T790M et ROS1

inferred← citeshttps://doi.org/10.1021/acs.analchem.5c07102openalex-snapshot

Preclinical Evaluation of Rationally Designed Peptide-NIRF Probe for c-Met Positive Liver Cancer Imaging-Guided Surgery

inferred← citeshttps://doi.org/10.1021/acs.chemrestox.8b00191openalex-snapshot

Evaluation of Deuterium-Labeled JNJ38877605: Pharmacokinetic, Metabolic, and in Vivo Antitumor Profiles

inferred← citeshttps://doi.org/10.1021/acs.chemrev.8b00467openalex-snapshot

The RTK Interactome: Overview and Perspective on RTK Heterointeractions

inferred← citeshttps://doi.org/10.1038/aps.2013.125openalex-snapshot

Yhhu3813 is a novel selective inhibitor of c-Met Kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells

inferred← citeshttps://doi.org/10.1038/emm.2017.17openalex-snapshot

Progress of antibody-based inhibitors of the HGF–cMET axis in cancer therapy

inferred← citeshttps://doi.org/10.1038/mt.2016.95openalex-snapshot

Sequence-defined cMET/HGFR-targeted Polymers as Gene Delivery Vehicles for the Theranostic Sodium Iodide Symporter (NIS) Gene

inferred← citeshttps://doi.org/10.1038/ncomms7044openalex-snapshot

Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas

inferred← citeshttps://doi.org/10.1038/nrclinonc.2017.40openalex-snapshot

Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges

inferred← citeshttps://doi.org/10.1038/onc.2015.172openalex-snapshot

Rethinking pheochromocytomas and paragangliomas from a genomic perspective

inferred← citeshttps://doi.org/10.1038/s41392-020-00324-2openalex-snapshot

Overview of current targeted therapy in gallbladder cancer

inferred← citeshttps://doi.org/10.1038/s41392-020-0116-zopenalex-snapshot

Comprehensive review of targeted therapy for colorectal cancer

inferred← citeshttps://doi.org/10.1038/s41392-021-00572-wopenalex-snapshot

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

inferred← citeshttps://doi.org/10.1038/s41392-024-01899-wopenalex-snapshot

Therapeutic advances of targeting receptor tyrosine kinases in cancer

inferred← citeshttps://doi.org/10.1038/s41392-024-01937-7openalex-snapshot

Pre-metastatic niche: formation, characteristics and therapeutic implication

inferred← citeshttps://doi.org/10.1038/s41467-019-10025-2openalex-snapshot

Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p

inferred← citeshttps://doi.org/10.1038/s41467-019-13034-3openalex-snapshot

EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming

inferred← citeshttps://doi.org/10.1038/s41598-020-60143-xopenalex-snapshot

MiR-23b-3p reduces the proliferation, migration and invasion of cervical cancer cell lines via the reduction of c-Met expression

inferred← citeshttps://doi.org/10.1038/s41598-023-38116-7openalex-snapshot

HGF/c-Met signaling promotes the migration and proliferation of deer antler MSCs

inferred← citeshttps://doi.org/10.1038/s41698-025-01144-9openalex-snapshot

MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer

inferred← citeshttps://doi.org/10.1038/srep11749openalex-snapshot

INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models

inferred← citeshttps://doi.org/10.1038/srep38502openalex-snapshot

c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma

inferred← citeshttps://doi.org/10.1039/c5cp07001eopenalex-snapshot

Allosteric inhibition of c-Met kinase in sub-microsecond molecular dynamics simulations induced by its inhibitor, tivantinib

inferred← citeshttps://doi.org/10.1039/c5ra04109kopenalex-snapshot

A new method to determine the new C-Met inhibitor “Cabozantinib” in dosage form and human plasma via micelle-enhanced spectrofluorimetry

inferred← citeshttps://doi.org/10.1039/d1tb00408eopenalex-snapshot

A novel peptide targeting c-Met for hepatocellular carcinoma diagnosis

inferred← citeshttps://doi.org/10.1080/13543776.2022.2008356openalex-snapshot

An updated patent review of small-molecule c-Met kinase inhibitors (2018-present)

inferred← citeshttps://doi.org/10.1080/13543784.2016.1175435openalex-snapshot

Investigational drugs for head and neck cancer

inferred← citeshttps://doi.org/10.1080/17460441.2019.1551355openalex-snapshot

Optimization techniques for novel c-Met kinase inhibitors

inferred← citeshttps://doi.org/10.1080/2162402x.2016.1219828openalex-snapshot

Peritumoral stromal neutrophils are essential for c-Met-elicited metastasis in human hepatocellular carcinoma

inferred← citeshttps://doi.org/10.1089/hum.2017.217openalex-snapshot

Hepatocyte Growth Factor Gene Therapy for Ischemic Diseases

inferred← citeshttps://doi.org/10.1093/ejcts/ezv323openalex-snapshot

Clinical impact of c-MET expression and mutational status in patients with colorectal cancer lung metastases

inferred← citeshttps://doi.org/10.1093/pcmedi/pbab017openalex-snapshot

A case report of response to crizotinib in chemotherapy-refractory metastatic gallbladder cancer with met amplification and acquired resistance resulting from the loss of MET amplification

inferred← citeshttps://doi.org/10.1097/cco.0b013e32835daf37openalex-snapshot

Targeting c-MET in the battle against advanced nonsmall-cell lung cancer

inferred← citeshttps://doi.org/10.1097/cco.0b013e328363e0daopenalex-snapshot

Angiogenesis as a target for the treatment of ovarian cancer

inferred← citeshttps://doi.org/10.1097/coc.0000000000000202openalex-snapshot

The Prognostic Significance of c-MET and EGFR Overexpression in Resected Gastric Adenocarcinomas

inferred← citeshttps://doi.org/10.1097/hep.0000000000000206openalex-snapshot

Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma

inferred← citeshttps://doi.org/10.1097/jto.0000000000000183openalex-snapshot

A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non–Small-Cell Lung Cancer

inferred← citeshttps://doi.org/10.1101/cshperspect.a016949openalex-snapshot

Endocytosis and Cancer

inferred← citeshttps://doi.org/10.1111/bjh.12270openalex-snapshot

Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease

inferred← citeshttps://doi.org/10.1111/cas.14511openalex-snapshot

Circular RNA LPAR3 sponges microRNA‐198 to facilitate esophageal cancer migration, invasion, and metastasis

inferred← citeshttps://doi.org/10.1111/his.12475openalex-snapshot

Amplification and overexpression of CMET is a common event in brain metastases of non‐small cell lung cancer

inferred← citeshttps://doi.org/10.1111/his.12709openalex-snapshot

Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cM et as a negative prognostic factor

inferred← citeshttps://doi.org/10.1111/jop.12478openalex-snapshot

Combined CD 44, c‐ MET , and EGFR expression in p16‐positive and p16‐negative head and neck squamous cell carcinomas

inferred← citeshttps://doi.org/10.1124/pr.113.007625openalex-snapshot

Interrogating Tumor Metabolism and Tumor Microenvironments Using Molecular Positron Emission Tomography Imaging. Theranostic Approaches to Improve Therapeutics

inferred← citeshttps://doi.org/10.1126/scisignal.2003884openalex-snapshot

Epigenetic Activation of AP1 Promotes Squamous Cell Carcinoma Metastasis

inferred← citeshttps://doi.org/10.1136/bmjopen-2021-049575openalex-snapshot

Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis

inferred← citeshttps://doi.org/10.1136/jclinpath-2012-201375openalex-snapshot

Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas

inferred← citeshttps://doi.org/10.1155/2013/341636openalex-snapshot

Targeting the HGF-cMET Axis in Hepatocellular Carcinoma

inferred← citeshttps://doi.org/10.1158/0008-5472.can-14-0826openalex-snapshot

Targeting the c-Met/FZD8 Signaling Axis Eliminates Patient-Derived Cancer Stem–like Cells in Head and Neck Squamous Carcinomas

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-14-0264openalex-snapshot

Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Using 3′-Deoxy-3′-[18F]-Fluorothymidine Positron Emission Tomography

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-14-1293openalex-snapshot

Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-15-2323openalex-snapshot

Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-16-3273openalex-snapshot

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-17-3657openalex-snapshot

Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non–Small Cell Lung Cancer Detected by 18F-fluorothymidine

inferred← citeshttps://doi.org/10.1158/1535-7163.mct-14-1105openalex-snapshot

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

inferred← citeshttps://doi.org/10.1158/2643-3230.bcd-21-0055openalex-snapshot

Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis

inferred← citeshttps://doi.org/10.1159/000439431openalex-snapshot

Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for ‘Off-Target' Effects Not Mediated by c-Met Inhibition

inferred← citeshttps://doi.org/10.1177/0963689719851772openalex-snapshot

Pancreatic Stellate Cells Facilitate Perineural Invasion of Pancreatic Cancer via HGF/c-Met Pathway

inferred← citeshttps://doi.org/10.1177/1010428317699118openalex-snapshot

The c-Met receptor: Implication for targeted therapies in colorectal cancer

inferred← citeshttps://doi.org/10.1177/1177271917701126openalex-snapshot

Hepatocyte Growth Factor/C-Met Axis in Thyroid Cancer: From Diagnostic Biomarker to Therapeutic Target

inferred← citeshttps://doi.org/10.1177/1758835919855238openalex-snapshot

Targeting the SLIT/ROBO pathway in tumor progression: molecular mechanisms and therapeutic perspectives

inferred← citeshttps://doi.org/10.1177/1933719116648212openalex-snapshot

Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer: Importance of Targeting c-MET and HGF Interaction

inferred← citeshttps://doi.org/10.1186/s12885-015-1064-9openalex-snapshot

Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model

inferred← citeshttps://doi.org/10.1186/s12885-017-3177-9openalex-snapshot

Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways

inferred← citeshttps://doi.org/10.1186/s12943-018-0800-6openalex-snapshot

Targeting tumour microenvironment by tyrosine kinase inhibitor

inferred← citeshttps://doi.org/10.1186/s12964-017-0165-2openalex-snapshot

c-Met expression and activity in urogenital cancers – novel aspects of signal transduction and medical implications

inferred← citeshttps://doi.org/10.1186/s12964-025-02033-1openalex-snapshot

Targeting HGF/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion

inferred← citeshttps://doi.org/10.1186/s13046-021-01862-5openalex-snapshot

The FAM3C locus that encodes interleukin-like EMT inducer (ILEI) is frequently co-amplified in MET-amplified cancers and contributes to invasiveness

inferred← citeshttps://doi.org/10.1200/jco.2012.46.6185openalex-snapshot

Cabozantinib in Prostate Cancer: The Beginning of a Precision Paradigm?

inferred← citeshttps://doi.org/10.1200/jco.2015.64.7685openalex-snapshot

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O 6 -Methylguanine–DNA Methyltransferase Biomarker Analyses

inferred← citeshttps://doi.org/10.1245/s10434-013-3355-1openalex-snapshot

MET Gene Copy Number Gain is an Independent Poor Prognostic Marker in Korean Stage I Lung Adenocarcinomas

inferred← citeshttps://doi.org/10.1371/journal.pone.0128159openalex-snapshot

The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma

inferred← citeshttps://doi.org/10.1371/journal.pone.0152585openalex-snapshot

The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer

inferred← citeshttps://doi.org/10.14202/vetworld.2016.80-90openalex-snapshot

Recent developments in receptor tyrosine kinases targeted anticancer therapy

inferred← citeshttps://doi.org/10.14694/edbook_am.2014.34.e172openalex-snapshot

New Directions in Perioperative Management of Locally Advanced Esophagogastric Cancer

inferred← citeshttps://doi.org/10.1517/13543784.2013.824422openalex-snapshot

Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer

inferred← citeshttps://doi.org/10.1517/14712598.2013.827657openalex-snapshot

Targeted therapy for NSCLC with driver mutations

inferred← citeshttps://doi.org/10.1517/14728214.2013.842976openalex-snapshot

Emerging tyrosine kinase inhibitors for head and neck cancer

inferred← citeshttps://doi.org/10.1517/14728222.2014.938050openalex-snapshot

cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?

inferred← citeshttps://doi.org/10.1634/theoncologist.2016-0038openalex-snapshot

A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

inferred← citeshttps://doi.org/10.1634/theoncologist.2016-0223openalex-snapshot

A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer

inferred← citeshttps://doi.org/10.17816/clinpract4445-54openalex-snapshot

STEM CELL THERAPY OF MALIGNANT BRAIN TUMORS: REALITY AND PROSPECTS

inferred← citeshttps://doi.org/10.18632/oncotarget.15589openalex-snapshot

Hepatocyte growth factor is a prognostic marker in patients with colorectal cancer: a meta-analysis

inferred← citeshttps://doi.org/10.18632/oncotarget.1828openalex-snapshot

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit

inferred← citeshttps://doi.org/10.18632/oncotarget.2003openalex-snapshot

HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development

inferred← citeshttps://doi.org/10.18632/oncotarget.20087openalex-snapshot

Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review

inferred← citeshttps://doi.org/10.18632/oncotarget.20392openalex-snapshot

Prognostic value of c-Met overexpression in pancreatic adenocarcinoma: a meta-analysis

inferred← citeshttps://doi.org/10.18632/oncotarget.2049openalex-snapshot

HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

inferred← citeshttps://doi.org/10.18632/oncotarget.2078openalex-snapshot

Sulfatase 1 (hSulf-1) reverses basic fibroblast growth factor-stimulated signaling and inhibits growth of hepatocellular carcinoma in animal model

inferred← citeshttps://doi.org/10.18632/oncotarget.20796openalex-snapshot

Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review

inferred← citeshttps://doi.org/10.18632/oncotarget.20824openalex-snapshot

MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review

inferred← citeshttps://doi.org/10.18632/oncotarget.21303openalex-snapshot

Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review

inferred← citeshttps://doi.org/10.18632/oncotarget.23474openalex-snapshot

Correlation among genetic variations of c-MET in Chinese patients with non-small cell lung cancer

inferred← citeshttps://doi.org/10.18632/oncotarget.25472openalex-snapshot

Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors

inferred← citeshttps://doi.org/10.18632/oncotarget.27363openalex-snapshot

Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer

inferred← citeshttps://doi.org/10.18632/oncotarget.2771openalex-snapshot

Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells

inferred← citeshttps://doi.org/10.18632/oncotarget.3094openalex-snapshot

Functional consequence of theMET-T1010I polymorphism in breast cancer

inferred← citeshttps://doi.org/10.18632/oncotarget.3751openalex-snapshot

Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma

inferred← citeshttps://doi.org/10.18632/oncotarget.3937openalex-snapshot

The HGF inhibitory peptide HGP-1 displays promisingin vitroandin vivoefficacy for targeted cancer therapy

inferred← citeshttps://doi.org/10.18632/oncotarget.5151openalex-snapshot

c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations

inferred← citeshttps://doi.org/10.18632/oncotarget.5748openalex-snapshot

Isothiocyanatostilbenes as novel c-Met inhibitors

inferred← citeshttps://doi.org/10.18632/oncotarget.7043openalex-snapshot

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

inferred← citeshttps://doi.org/10.18632/oncotarget.8603openalex-snapshot

Gelsolin-mediated activation of PI3K/Akt pathway is crucial for hepatocyte growth factor-induced cell scattering in gastric carcinoma

inferred← citeshttps://doi.org/10.18632/oncotarget.8681openalex-snapshot

The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor

inferred← citeshttps://doi.org/10.20517/cdr.2022.09openalex-snapshot

An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer

inferred← citeshttps://doi.org/10.21037/jgo.2016.08.13openalex-snapshot

Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers

inferred← citeshttps://doi.org/10.21037/jgo.2018.08.18openalex-snapshot

Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets

inferred← citeshttps://doi.org/10.21037/tgh.2018.08.06openalex-snapshot

Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in epidermal growth factor receptor-2-negative, mesenchymal-epithelial transition-positive gastroesophageal adenocarcinoma: is it a real failure?

inferred← citeshttps://doi.org/10.21037/tlcr-19-339openalex-snapshot

Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis

inferred← citeshttps://doi.org/10.21203/rs.3.rs-34290/v1openalex-snapshot

HGF Treatment Promotes Cardiac Function and Cardiac Repair: Meta-analysis of Pig Models With Myocardial Infarction

inferred← citeshttps://doi.org/10.21203/rs.3.rs-34290/v2openalex-snapshot

Gene Therapy with Hepatocyte Growth Factor Improves Left Ventricular Systolic Function After Myocardial Infarction: A Systematic Review and Meta-analysis of Pig Models

inferred← citeshttps://doi.org/10.2147/itt.s37409openalex-snapshot

Development of antibody-based c-Met inhibitors for targeted cancer therapy

showing the first 200 of 267 · page through all 267

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.